FATE
Price
$1.68
Change
+$0.02 (+1.20%)
Updated
Dec 20 closing price
70 days until earnings call
MNOV
Price
$2.15
Change
-$0.01 (-0.46%)
Updated
Dec 20, 04:59 PM (EDT)
54 days until earnings call
Ad is loading...

FATE vs MNOV

Header iconFATE vs MNOV Comparison
Open Charts FATE vs MNOVBanner chart's image
Fate Therapeutics
Price$1.68
Change+$0.02 (+1.20%)
Volume$10.14M
CapitalizationN/A
Medicinova
Price$2.15
Change-$0.01 (-0.46%)
Volume$2.84K
CapitalizationN/A
FATE vs MNOV Comparison Chart
Loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
FATE vs. MNOV commentary
Dec 23, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is FATE is a Hold and MNOV is a Hold.

COMPARISON
Comparison
Dec 23, 2024
Stock price -- (FATE: $1.68 vs. MNOV: $2.17)
Brand notoriety: FATE and MNOV are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: FATE: 307% vs. MNOV: 94%
Market capitalization -- FATE: $192.48M vs. MNOV: $105.45M
FATE [@Biotechnology] is valued at $192.48M. MNOV’s [@Biotechnology] market capitalization is $105.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

FATE’s FA Score shows that 1 FA rating(s) are green whileMNOV’s FA Score has 0 green FA rating(s).

  • FATE’s FA Score: 1 green, 4 red.
  • MNOV’s FA Score: 0 green, 5 red.
According to our system of comparison, MNOV is a better buy in the long-term than FATE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

FATE’s TA Score shows that 3 TA indicator(s) are bullish while MNOV’s TA Score has 4 bullish TA indicator(s).

  • FATE’s TA Score: 3 bullish, 6 bearish.
  • MNOV’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, MNOV is a better buy in the short-term than FATE.

Price Growth

FATE (@Biotechnology) experienced а -8.20% price change this week, while MNOV (@Biotechnology) price change was +3.33% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

FATE is expected to report earnings on Mar 03, 2025.

MNOV is expected to report earnings on Feb 14, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
FATE($192M) has a higher market cap than MNOV($105M). MNOV YTD gains are higher at: 44.667 vs. FATE (-55.080). MNOV has higher annual earnings (EBITDA): -11.96M vs. FATE (-177.57M). FATE has more cash in the bank: 297M vs. MNOV (42.3M). MNOV has less debt than FATE: MNOV (202K) vs FATE (99M). FATE has higher revenues than MNOV: FATE (13.4M) vs MNOV (0).
FATEMNOVFATE / MNOV
Capitalization192M105M183%
EBITDA-177.57M-11.96M1,485%
Gain YTD-55.08044.667-123%
P/E RatioN/AN/A-
Revenue13.4M0-
Total Cash297M42.3M702%
Total Debt99M202K49,010%
FUNDAMENTALS RATINGS
FATE vs MNOV: Fundamental Ratings
FATE
MNOV
OUTLOOK RATING
1..100
5091
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
49
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9793
PRICE GROWTH RATING
1..100
9439
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

FATE's Valuation (18) in the Biotechnology industry is in the same range as MNOV (49). This means that FATE’s stock grew similarly to MNOV’s over the last 12 months.

FATE's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as MNOV (100). This means that FATE’s stock grew similarly to MNOV’s over the last 12 months.

MNOV's SMR Rating (93) in the Biotechnology industry is in the same range as FATE (97). This means that MNOV’s stock grew similarly to FATE’s over the last 12 months.

MNOV's Price Growth Rating (39) in the Biotechnology industry is somewhat better than the same rating for FATE (94). This means that MNOV’s stock grew somewhat faster than FATE’s over the last 12 months.

MNOV's P/E Growth Rating (100) in the Biotechnology industry is in the same range as FATE (100). This means that MNOV’s stock grew similarly to FATE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
FATEMNOV
RSI
ODDS (%)
Bullish Trend 4 days ago
88%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
76%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
81%
MACD
ODDS (%)
Bearish Trend 3 days ago
88%
Bearish Trend 3 days ago
76%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
72%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
90%
Bullish Trend 3 days ago
73%
Advances
ODDS (%)
Bullish Trend 14 days ago
86%
Bullish Trend 3 days ago
71%
Declines
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 10 days ago
83%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
86%
Aroon
ODDS (%)
Bearish Trend 3 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
FATE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MNOV
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SUUFF0.120.01
+12.67%
STRATHMORE PLUS URANIUM CORP.
NNOMF0.580.04
+6.92%
Nano One Materials Corp.
DSNKY28.150.37
+1.33%
Daiichi Sankyo Co., Ltd.
YAHOY5.42-0.05
-0.91%
LY Corporation
STRNY31.77-0.60
-1.87%
Severn Trent PLC

MNOV and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNOV has been loosely correlated with FATE. These tickers have moved in lockstep 36% of the time. This A.I.-generated data suggests there is some statistical probability that if MNOV jumps, then FATE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNOV
1D Price
Change %
MNOV100%
+0.46%
FATE - MNOV
36%
Loosely correlated
+1.20%
MNKD - MNOV
30%
Poorly correlated
+8.73%
VIR - MNOV
29%
Poorly correlated
-0.41%
TIL - MNOV
28%
Poorly correlated
+2.64%
QLGN - MNOV
28%
Poorly correlated
-3.47%
More